Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Preferred Stock Liabilities (2018 - 2019)

Bicycle Therapeutics (BCYC) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $54.6 million as the latest value for Q1 2019.

  • For Q1 2019, Preferred Stock Liabilities rose 30.61% year-over-year to $54.6 million; the TTM value through Mar 2019 reached $54.6 million, up 30.61%, while the annual FY2018 figure was $25.8 million, 38.41% down from the prior year.
  • Preferred Stock Liabilities hit $54.6 million in Q1 2019 for Bicycle Therapeutics, up from $25.8 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $54.6 million in Q2 2018 and bottomed at $25.8 million in Q4 2018.